Eric J Pappert

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi Toxin-induced movement disorders
    Eric J Pappert
    Division of Neurology, Department of Medicine, University of Texas, Health Science Center, 2379 NE Loop 410, Suite 12, San Antonio, TX 78217, USA
    Neurol Clin 23:429-59. 2005
  2. ncbi Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial
    Eric J Pappert
    Solstice Neurosciences, Inc, Malvern, Pennsylvania, USA
    Mov Disord 23:510-7. 2008
  3. ncbi An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia
    Robert Chinnapongse
    Solstice Neurosciences, LLC, Louisville, Kentucky 40207, USA
    Int J Neurosci 120:703-10. 2010
  4. ncbi Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study
    Richard M Trosch
    The Parkinson s Disease and Movement Disorders Center, 26400 W, Southfield, Michigan, USA
    Mov Disord 22:1258-64. 2007

Detail Information

Publications4

  1. ncbi Toxin-induced movement disorders
    Eric J Pappert
    Division of Neurology, Department of Medicine, University of Texas, Health Science Center, 2379 NE Loop 410, Suite 12, San Antonio, TX 78217, USA
    Neurol Clin 23:429-59. 2005
    ..As an example, the MPTP model has not only provided an animal model to study therapeutic strategies in PD but has also contributed important insights into the mechanism of neuronal degeneration...
  2. ncbi Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial
    Eric J Pappert
    Solstice Neurosciences, Inc, Malvern, Pennsylvania, USA
    Mov Disord 23:510-7. 2008
    ..Mild dry mouth was more frequent with BoNT-B but there were no differences for moderate/severe dry mouth. In this study, both BoNT-A and B were shown to be effective and safe for the treatment of toxin-naive CD subjects...
  3. ncbi An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia
    Robert Chinnapongse
    Solstice Neurosciences, LLC, Louisville, Kentucky 40207, USA
    Int J Neurosci 120:703-10. 2010
    ..Evaluate the safety and efficacy of a sequential dose escalation of rimabotulinumtoxinB (BoNT-B) in cervical dystonia (CD) subjects...
  4. ncbi Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study
    Richard M Trosch
    The Parkinson s Disease and Movement Disorders Center, 26400 W, Southfield, Michigan, USA
    Mov Disord 22:1258-64. 2007
    ..Evaluate the safety of botulinum toxin type B (BoNT-B) in subjects with hemifacial spasm (HFS)...